NN (NNBR) 10-Q 10 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 03, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Trading Symbol	NNBR
Entity Registrant Name	NN INC
Entity Central Index Key	918,541
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		27,666,389

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income (Loss) (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
Net sales	$ 169,148	$ 157,555
Cost of sales (exclusive of depreciation and amortization shown separately below)	126,444	114,480
Selling, general and administrative expense	22,177	16,641
Acquisition related costs excluded from selling, general and administrative expense	1,776
Depreciation and amortization	14,281	12,571
Other operating expense	22
Restructuring and integration expense	755	11
Income from operations	3,693	13,852
Interest expense	11,996	14,839
Derivative gain on change in interest rate swap fair value		(88)
Other income, net	(313)	(722)
Loss from continuing operations before benefit for income taxes and share of net income from joint venture	(7,990)	(177)
Benefit for income taxes	1,176	377
Share of net income from joint venture	831	1,693
Income (loss) from continuing operations	(5,983)	1,893
Income from discontinued operations, net of tax (Note 2)		5,518
Net income (loss)	(5,983)	7,411
Other comprehensive income (loss):
Foreign currency translation gain	5,465	5,105
Other comprehensive income	5,465	5,105
Comprehensive income (loss)	$ (518)	$ 12,516
Basic net income (loss) per share:
Income (loss) from continuing operations per share	$ (0.22)	$ 0.07
Income from discontinued operations per share		0.20
Net income (loss) per share	$ (0.22)	$ 0.27
Weighted average shares outstanding	27,597	27,303
Diluted net income (loss) per share:
Income (loss) from continuing operations per share	$ (0.22)	$ 0.07
Income from discontinued operations per share		0.20
Net income (loss) per share	$ (0.22)	$ 0.27
Weighted average shares outstanding	27,597	27,634
Cash dividends per common share	$ 0.07	$ 0.07

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Current assets:
Cash and cash equivalents	$ 184,955	$ 224,446
Accounts receivable, net	119,615	108,446
Inventories	91,559	82,617
Income tax receivable	43,866	43,253
Other current assets	21,106	18,518
Total current assets	461,101	477,280
Property, plant and equipment, net	266,926	259,280
Goodwill	463,694	454,612
Intangible assets, net	237,605	237,702
Investment in joint venture	42,110	39,822
Other non-current assets	13,646	6,307
Total assets	1,485,082	1,475,003
Current liabilities:
Accounts payable	54,788	52,990
Accrued salaries, wages and benefits	26,496	21,145
Current maturities of long-term debt	18,796	17,283
Other current liabilities	22,264	17,003
Total current liabilities	122,344	108,421
Deferred tax liabilities	71,499	71,564
Non-current income tax payable	5,593	5,593
Long-term debt, net of current portion	787,438	790,805
Other non-current liabilities	13,349	12,516
Total liabilities	1,000,223	988,899
Commitments and contingencies (Note 12)
Total stockholders' equity	484,859	486,104
Total liabilities and stockholders' equity	$ 1,485,082	$ 1,475,003

Condensed Consolidated Stateme4

Condensed Consolidated Statement of Changes in Stockholders' Equity (Unaudited) - 3 months ended Mar. 31, 2018 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (loss) [Member]
Beginning Balance at Dec. 31, 2017	$ 486,104	$ 275	$ 292,494	$ 211,080	$ (17,745)
Beginning Balance, Shares at Dec. 31, 2017		27,572
Net loss	(5,983)			(5,983)
Dividends declared	(1,955)			(1,955)
Share-based compensation expense	1,256	$ 1	1,255
Share-based compensation expense, shares		87
Shares issued for option exercises	$ 242		242
Shares issued for option exercises, shares	23	23
Restricted shares forgiven for taxes and forfeited	$ (287)		(287)
Restricted shares forgiven for taxes and forfeited, shares		(16)
Foreign currency translation gain (loss)	5,465				5,465
Adoption of new accounting standard (Note 1)	17			17
Ending Balance at Mar. 31, 2018	$ 484,859	$ 276	$ 293,704	$ 203,159	$ (12,280)
Ending Balance, Shares at Mar. 31, 2018		27,666

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Cash flows from operating activities:
Net income (loss)	$ (5,983)	$ 7,411
Adjustments to reconcile net income (loss) to net cash provided by (used by) operating activities:
Depreciation and amortization of continuing operations	14,281	12,571
Depreciation and amortization of discontinued operations		3,009
Amortization of debt issuance costs	1,088	1,221
Share of net income from joint venture, net of cash dividends received	(831)	(1,693)
Compensation expense from issuance of share-based awards	1,256	1,152
Other	347	(207)
Changes in operating assets and liabilities:
Accounts receivable	(9,433)	(19,332)
Inventories	(7,791)	(1,025)
Accounts payable	(296)	1,394
Income taxes receivable	(613)	5,899
Other	7,001	(5,459)
Net cash provided by (used by) operating activities	(974)	4,941
Cash flows from investing activities:
Acquisition of property, plant and equipment	(11,860)	(8,565)
Cash paid to acquire businesses, net of cash received	(14,676)
Cash paid for earnest money for Paragon Medical acquisition (Note 3)	(6,000)
Other	(282)	295
Net cash provided by (used by) investing activities	(32,818)	(8,270)
Cash flows from financing activities:
Dividends paid	(1,931)	(1,910)
Proceeds from long-term debt	10,000	14,000
Repayment of long-term debt	(13,000)	(1,437)
Repayments of short-term debt, net	(52)	(2,045)
Other	(1,278)	(316)
Net cash provided by (used by) financing activities	(6,261)	8,292
Effect of exchange rate changes on cash flows	562	215
Net change in cash and cash equivalents	(39,491)	5,178	[1]
Cash and cash equivalents at beginning of period	224,446	14,405	[2]
Cash and cash equivalents at end of period	$ 184,955	$ 19,583
[1]	Cash and cash equivalents includes $8.1 million of cash and cash equivalents that were included in current assets of discontinued operations as of December 31, 2016.
[2]	Cash and cash equivalents includes $10.9 million of cash and cash equivalents that were included in current assets of discontinued operations as of March 31, 2017.

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2017	Dec. 31, 2016
Statement of Cash Flows [Abstract]
Cash included in current assets of discontinued operations	$ 10.9	$ 8.1

Interim Financial Statements

Interim Financial Statements	3 Months Ended
	Mar. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Interim Financial Statements	Note 1. Interim Financial Statements Nature of Business NN, Inc., is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth 10-Q, In January 2018, we implemented a new enterprise and management structure designed to accelerate growth and further balance our portfolio by aligning our strategic assets and businesses. Our businesses were reorganized into the Mobile Solutions, Power Solutions, and Life Sciences divisions and are based principally on the end markets they serve. The Autocam Precision Components Group reported in our historical financial statements was renamed as the Mobile Solutions division. The Mobile Solutions division is focused on growth in the industrial and automotive end markets. The Precision Engineered Products Group reported in our historical financial statements was bifurcated into two new divisions – Power Solutions and Life Sciences. The Power Solutions division is focused on growth in the electrical and aerospace and defense end markets. The Life Sciences division is focused on growth in the medical end market. Basis of Presentation The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2017, was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report on Form 10-Q. Except for per share data or as otherwise indicated, all dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands. Prior Periods’ Financial Statement Revision As disclosed in our 2017 Annual Report on Form10-K, we identified various misstatements in our previously issued 2016 and 2015 annual financial statements and interim periods in 2016 and 2017. These prior period errors related primarily to (i) accounting for income and franchise taxes, (ii) accounting for the gain on the disposition of a business, (iii) accounting for indemnification assets related to a prior acquisition, (iv) accounting for foreign currency transactions, (v) accounting for the translation of foreign subsidiary assets and joint venture, and (vi) other immaterial errors, including errors that had previously been adjusted for as out of period corrections in the periods identified. We assessed the materiality of the misstatements on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to any prior annual or interim periods. In accordance with ASC 250 (SAB Topic 1.N, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements Accounting Standards Recently Adopted Revenue Recognition Revenue from Contracts with Customers Revenue Recognition, Definition of a Business. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, Statement of Cash Flows. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) The new cash flow guidance requires that cash payments for debt prepayment costs be classified as cash outflows for financing activities. We paid $31.6 million for debt prepayment costs in April 2017. These debt prepayment costs were previously classified as cash outflows from operating activities in 2017. Under the new guidance, these costs will be reclassified to cash outflows from financing activities when these comparable periods are presented in future filings. The new guidance also requires entities to make an accounting policy election regarding classification of distributions received from equity method investees. Existing guidance does not currently address how an entity should determine which distributions represent returns on versus returns of investment. The lack of specific guidance has resulted in diversity in practice. The two allowable approaches are the “cumulative earnings” approach and the “nature of the distribution” approach, as defined by ASU 2016-15. Accounting Standards Not Yet Adopted Leases. 2016-02, Leases 2016-02 Leases, Leases. 2016-02 right-of-use Goodwill. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, Effects of Tax Reform in Other Comprehensive Income. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, 2018-02

Discontinued Operations

Discontinued Operations	3 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 2. Discontinued Operations On August 17, 2017, we completed the sale of our global precision bearing components business (the “PBC Business”). The PBC Business included all our facilities that were engaged in the production of precision steel balls, steel rollers, and metal retainers and automotive specialty products used primarily in the bearing industry. The sale of the PBC Business furthers management’s long-term strategy to build a diversified industrial business with a comprehensive geographic footprint in attractive high-growth market segments. The PBC Business represented all of the Precision Bearing Components Group reportable segment disclosed in our historical financial statements. In accordance with ASC 205-20, Presentation of Financial Statements – Discontinued Operations The following table summarizes the major line items included in the results of operations of the discontinued operations. Three Months Ended Net sales $ 68,759 Cost of sales (exclusive of depreciation and amortization shown separately below) 52,959 Selling, general and administrative expense 4,353 Depreciation and amortization 3,009 Restructuring and integration expense 129 Income from operations 8,309 Gain on disposal of discontinued operations — Interest income 117 Interest and other income (expense) (2 ) Income from discontinued operations before provision (benefit) for income taxes 8,194 Provision for income taxes 2,676 Income from discontinued operations, net of tax $ 5,518 The following table presents the significant noncash items and cash paid for capital expenditures of discontinued operations. Three Months Ended Depreciation and amortization $ 3,009 Acquisition of property, plant and equipment $ 2,483

Acquisitions

Acquisitions	3 Months Ended
	Mar. 31, 2018
Business Combinations [Abstract]
Acquisitions	Note 3. Acquisitions Bridgemedica, LLC On February 22, 2018, we completed the acquisition of 100% of the assets of Bridgemedica, LLC (“Bridgemedica”). Bridgemedica is a medical device company that provides concept to supply solutions through design, development engineering and manufacturing. Operating results of Bridgemedica are reported prospectively in our Life Sciences division. We are in the process of analyzing the opening balance sheet and purchase price allocation. Amounts recorded for preliminary goodwill and intangible assets are disclosed in Note 6 and Note 7, respectively. Other In March 2018, we paid $6.0 million in earnest money to the previous owners of PMG Intermediate Holding Corporation. See Note 18 for the subsequent event disclosure.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment Information	Note 4. Segment Information We determined our reportable segments under the provisions of U.S. GAAP related to disclosures about segments of an enterprise. Management has concluded that Mobile Solutions, Power Solutions, and Life Sciences each constitutes an operating segment as each engages in business activities for which it earns revenues and incurs expenses for which separate financial information is available, and this is the level at which the Chief Operating Decision Maker (“CODM”) reviews discrete financial information for purposes of allocating resources and assessing performance. In making this determination, management considered the form and content of the financial information that is regularly reviewed by the CODM. As described in Note 1, in January 2018, we implemented a new enterprise and management structure and reorganized our businesses into the Mobile Solutions, Power Solutions and Life Sciences divisions based principally on the end markets they serve. In the first quarter of 2018, we began reporting our financial results based on these new reportable segments. Prior year amounts have been restated to conform to the current year presentation. Mobile Solutions Our Mobile Solutions division is focused on growth in the industrial and automotive end markets. Within this division we manufacture highly engineered, difficult-to-manufacture We sell a wide range of highly engineered, extremely close tolerance, precision-machined metal components and subassemblies primarily to the automotive and general industrial end markets. We have developed an expertise in manufacturing highly complex, system critical components for fuel systems, engines and transmissions, power steering systems and electromechanical motors on a high-volume basis. This expertise has been gained through investment in technical capabilities, processes and systems, and skilled program management and product launch capabilities. Power Solutions Our Power Solutions division is focused on growth in the electrical, and aerospace and defense end markets. Within this division we combine materials science expertise with advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies and finished devices used in applications ranging from power control to flight control and for military devices. We manufacture a variety of products including electrical contacts, connectors, contact assemblies and precision stampings for the electrical end market and high precision products for the aerospace and defense end markets utilizing our extensive process technologies for optical grade plastics, thermally conductive plastics, titanium, Inconel, magnesium and electroplating. Life Sciences Our Life Sciences division is focused on growth in the medical end market. Within this division we combine advanced engineering and production capabilities to design and manufacture a broad range of high-precision metal and plastic components, assemblies and finished devices. We manufacture a variety of components, assemblies and instruments, such as surgical knives, bioresorbable implants, surgical staples, orthopedic system tools, laparoscopic devices, and drug delivery devices for the medical and life sciences end market. Segment Results The following table presents results of continuing operations for each reportable segment. Mobile Power Life Corporate and Total Three Months Ended March 31, 2018 Net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) (a) $ 169,148 Income (loss) from operations $ 9,785 $ 5,233 $ 4,204 $ (15,529 ) $ 3,693 Interest expense (11,996 ) Other income, net 313 Loss from continuing operations before benefit for income taxes and share of net income from joint venture $ (7,990 ) Three Months Ended March 31, 2017 Net sales $ 86,446 $ 48,424 $ 23,129 $ (444 ) $ 157,555 Income (loss) from operations $ 10,601 $ 6,795 $ 3,622 $ (7,166 ) $ 13,852 Interest expense (14,839 ) Other 810 Loss from continuing operations before benefit for income taxes and share of net income from joint venture $ (177 ) (a) Includes eliminations of intersegment transactions occurring during the ordinary course of business. Total Assets as of March 31, December 31, Mobile Solutions $ 453,521 $ 428,321 Power Solutions 393,048 383,063 Life Sciences 362,744 355,703 Corporate and Consolidations 275,769 307,916 Total Continuing Operations $ 1,485,082 $ 1,475,003 The Bridgemedica business acquired on February 22, 2018, contributed $1.3 million to net sales and $0.1 million to income from operations in the Life Sciences division after the acquisition date through March 31, 2018.

Inventories

Inventories	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventories	Note 5. Inventories Inventories are comprised of the following amounts: March 31, December 31, Raw materials $ 38,151 $ 37,337 Work in process 32,124 27,669 Finished goods 21,284 17,611 Inventories $ 91,559 $ 82,617

Goodwill

Goodwill	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 6. Goodwill The following table shows changes in the carrying amount of goodwill. Mobile Power Life Total Balance as of December 31, 2017 $ 74,147 $ 201,881 $ 178,584 $ 454,612 Currency impacts 295 719 — 1,014 Goodwill acquired in acquisition — — 7,867 7,867 Adjustments to goodwill — — 201 201 Balance as of March 31, 2018 $ 74,442 $ 202,600 $ 186,652 $ 463,694 The goodwill acquired in 2018 is related to the Bridgemedica acquisition as described in Note 3 and is derived from the value of the business acquired. We are in the process of analyzing the opening balance sheet and purchase price allocation. The preliminary fair value of the business acquired was based on management business plans and future performance estimates which are subject to a high degree of management judgment and complexity. Actual results may differ from these projections and the differences may be material, leading to measurement period adjustments of this goodwill. In the first quarter of 2018, as a result of the changes in our organizational and management structure, goodwill was reassigned to operating segments using a relative fair value allocation. For further information on the organizational changes, see Note 1.

Intangible Assets, Net

Intangible Assets, Net	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets, Net	Note 7. Intangible Assets, Net The following table shows changes in the carrying amount of intangible assets, net. Mobile Power Life Total Balance as of December 31, 2017 $ 39,446 $ 105,030 $ 93,226 $ 237,702 Amortization (873 ) (2,725 ) (2,397 ) (5,995 ) Currency impacts (15 ) — — (15 ) Intangible assets acquired in acquisition — — 5,913 5,913 Balance as of March 31, 2018 $ 38,558 $ 102,305 $ 96,742 $ 237,605 We added approximately $5.9 million of intangible assets during the three months ended March 31, 2018, primarily related to customer relationships acquired in the Bridgemedica acquisition with an estimated useful life of 13 years. In the first quarter of 2018, as a result of the changes in our organizational and management structure, intangible assets were reassigned to operating segments using a relative fair value allocation. For further information on the organizational changes, see Note 1.

Investment in Joint Venture

Investment in Joint Venture	3 Months Ended
	Mar. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Investment in Joint Venture	Note 8. Investment in Joint Venture We own a 49% investment in a joint venture located in Wuxi, China, called Wuxi Weifu Autocam Precision Machinery Company, Ltd. (the “JV”). The JV is jointly controlled and managed, and we account for it under the equity method. The following table summarizes activity related to our investment in the JV. Balance as of December 31, 2017 $ 39,822 Our share of cumulative earnings 957 Accretion of basis difference from purchase accounting (126 ) Foreign currency translation gain 1,457 Balance as of March 31, 2018 $ 42,110 We recognized sales to the JV of less than $0.2 million and approximately $0.1 million during the three-month periods ended March 31, 2018 and 2017, respectively. The following tables show selected financial data of the joint venture. March 31, December 31, Current assets $ 58,517 $ 47,600 Non-current 32,844 24,763 Total assets $ 91,361 $ 72,363 Current liabilities $ 41,504 $ 26,165 Total liabilities $ 41,504 $ 26,165 Three Months Ended March 31, 2018 2017 Net sales $ 18,003 $ 19,111 Cost of sales $ 15,147 $ 14,436 Income from operations $ 2,508 $ 4,411 Net income $ 1,952 $ 3,689

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	Note 9. Income Taxes On December 22, 2017, the U. S. government enacted comprehensive tax legislation. The Tax Act reduces the U.S. federal corporate income tax rate from 35% to 21% and creates new taxes on certain foreign sourced earnings. In response to the Tax Act, the Securities and Exchange Commission issued Staff Accounting Bulletin No. 118 (“SAB 118”) which allows issuers to recognize provisional estimates of the impact of the Tax Act in their financial statements, or in circumstances where estimates cannot be made, to disclose and recognize at a later date. For the year ended December 31, 2017, we included in our financial statements provisional charges for the revaluation of our net domestic deferred tax assets and a one-time one-year Our annualized effective tax rate from continuing operations was 14.7% for the three months ended March 31, 2018, and 213.0% for the three months ended March 31, 2017. Our 2018 effective tax rate differs from the U.S. federal statutory tax rate of 21% due to permanent differences including certain provisions of the Tax Act, specifically the base-broadening provision which imposed a new minimum tax on global intangible low-tax During the quarter ended March 31, 2018, we finalized our accounting policy decision with respect to the new GILTI tax rules and have concluded that GILTI will be treated as a periodic charge in the year in which it arises. Therefore, we will not record deferred taxes for the basis associated with GILTI earnings. During the third quarter of 2017, the Internal Revenue Service commenced an examination of the federal tax return for the pre-acquisition

Debt

Debt	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Debt	Note 10. Debt The following table presents debt balances as of March 31, 2018, and December 31, 2017. March 31, December 31, $545.0 million Senior Secured Term Loan B (“Senior Secured Term Loan”) bearing interest at the greater of 0.75% or one-month $ 534,250 $ 534,250 $300.0 million Incremental Term Loan (“Incremental Term Loan”) bearing interest at one-month LIBOR (1.88% at March 31, 2018), plus an applicable margin of 3.25% at March 31, 2018, expiring April 3, 2021 288,000 291,000 $143.0 million Senior Secured Revolver (“Senior Secured Revolver”) bearing interest at one-month LIBOR (1.88% at March 31, 2018) plus an applicable margin of 3.5% at March 31, 2018, expiring October 19, 2020 — — French Safeguard Obligations 299 290 Brazilian lines of credit and equipment notes 207 257 Chinese line of credit, bearing interest 2,868 2,768 Total 825,624 828,565 Less current maturities of long-term debt 18,796 17,283 Principal, net of current portion 806,828 811,282 Less unamortized debt issuance costs 19,390 20,477 Long-term debt, net of current portion $ 787,438 $ 790,805 We capitalized interest costs amounting to $0.2 million and $0.4 million in the three-months ended March 31, 2018, and 2017, related to construction in progress.

Restructuring and Integration

Restructuring and Integration	3 Months Ended
	Mar. 31, 2018
Restructuring and Related Activities [Abstract]
Restructuring and Integration	Note 11. Restructuring and Integration The following table summarizes restructuring and integration charges incurred for the three-month periods ended March 31, 2018 and 2017. Three Months Ended March 31, 2018 Mobile Power Life Corporate and Total Severance and other employee costs $ — $ — $ — $ 728 $ 728 Other 27 — — — 27 Total $ 27 $ — $ — $ 728 $ 755 Three Months Ended March 31, 2017 Mobile Power Life Corporate and Total Severance and other employee costs $ 11 $ — $ — $ — $ 11 Total $ 11 $ — $ — $ — $ 11 The following table summarizes restructuring and integration reserve activity for the three months ended March 31, 2018. Reserve Balance as of Charges Non-cash Cash Reserve Balance as of Severance and other employee costs $ — $ 728 $ — $ (95 ) $ 633 Site closure and other associated costs 1,099 27 (31 ) (583 ) 512 Total $ 1,099 $ 755 $ (31 ) $ (678 ) $ 1,145 We recognized severance costs of $0.7 million at corporate headquarters related to the restructuring of our former Precision Engineered Products Group to form the Power Solutions and Life Sciences divisions effective January 2, 2018. We are continually identifying restructuring and integration costs at our divisions. Future filings will include updates to these activities along with a reconciliation of beginning and ending liabilities. We expect to pay the entire reserve balance within no more than twelve months.

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 12. Commitments and Contingencies Brazil ICMS Tax Matter Prior to the acquisition of Autocam Corporation in 2014 (“Autocam”), Autocam’s Brazilian subsidiary received notification from the Brazilian tax authorities regarding ICMS (state value added tax or VAT) tax credits claimed on intermediary materials (tooling and perishable items) used in the manufacturing process. The Brazilian tax authority notification disallowed state ICMS credits claimed on intermediary materials based on the argument that these items are not intrinsically related to the manufacturing processes. Autocam Brazil filed an administrative defense with the Brazilian tax authority arguing, among other matters, that it should qualify for an ICMS tax credit, contending that the intermediary materials are directly related to the manufacturing process. We believe that we have substantial legal and factual defenses, and we plan to defend our interests in this matter vigorously. While we believe a loss is not probable, we estimate the range of possible losses related to this assessment is from $0 to $6.0 million. No amount was accrued at March 31, 2018, for this matter. There was no material change in the status of this matter from December 31, 2017, to March 31, 2018. We are entitled to indemnification from the former shareholders of Autocam, subject to the limitations and procedures set forth in the agreement and plan of merger relating to the Autocam acquisition. Management believes the indemnification would include amounts owed for the tax, interest and penalties related to this matter. All Other Legal Matters All other legal proceedings are of an ordinary and routine nature and are incidental to our operations. Management believes that such proceedings should not, individually or in the aggregate, have a material adverse effect on our business, financial condition, results of operations or cash flows. In making that determination, we analyze the facts and circumstances of each case at least quarterly in consultation with our attorneys and determine a range of reasonably possible outcomes.

Revenue from Contracts with Cus

Revenue from Contracts with Customers	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue from Contracts with Customers	Note 13. Revenue from Contracts with Customers We adopted ASC 606 on January 1, 2018, using the modified retrospective transition method for all contracts not completed as of the date of adoption. The reported results for 2018 reflect the application of ASC 606 while the reported results for 2017 were prepared under the guidance of ASC 605. The adoption of ASC 606 represents a change in accounting principle that will more closely align revenue recognition with the delivery of our goods and will provide financial statement readers with enhanced disclosures. In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods in an amount that reflects the consideration we expect to be entitled to receive in exchange for those goods. To the extent that transaction price includes variable consideration, we estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in management’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Revenue is recognized when control of the good or service is transferred to the customer, either at a point in time or as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services. The following table summarizes sales to external customers by major source. Three Months Ended March 31, 2018 Mobile Power Life Intersegment Total United States $ 49,655 $ 40,128 $ 30,553 $ (528 ) $ 119,808 China 11,581 1,485 126 — 13,192 Mexico 7,236 3,197 172 — 10,605 Brazil 9,885 50 — — 9,935 Poland 2,052 14 — — 2,066 Czech Republic 1,810 — — — 1,810 Italy 1,577 98 — — 1,675 Germany 1,534 7 1 — 1,542 Switzerland 1,406 — — — 1,406 Netherlands — 974 — — 974 Other 3,058 2,729 348 — 6,135 Total net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) $ 169,148 Product Sales We generally transfer control and recognize a sale when we ship the product from our manufacturing facility to our customer, at a point in time, as this is when our customer obtains the ability to direct use of, and obtain substantially all of the remaining benefits from, the goods. We have elected to recognize the cost for freight and shipping when control over products has transferred to the customer as a component of cost of sales. We use an observable price to determine the stand-alone selling price for separate performance obligations or a cost-plus-margin approach when an observable price is not available. The expected duration of our contracts is less than one year, and we have elected to apply the practical expedient that allows entities to disregard the effects of financing when the contract length is less than one year. The amount of consideration we receive and the revenue we recognize varies with volume rebates and incentives we offer to our customers. We estimate the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method depending on the nature of the variable consideration. Variable consideration is included in the transaction price if, in our judgement, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. We have utilized certain practical expedients allowed by the new standard. We intend to utilize the portfolio approach practical expedient to evaluate sales-related discounts on a portfolio basis to contracts with similar characteristics. We expect that the effect on our financial statements of applying the portfolio approach would not differ materially from applying the new standard to individual contracts. We give our customers the right to return only defective products in exchange for functioning products or rework of the product. These transactions are evaluated and accounted for under ASC Topic 460, Guarantees, Other Sources of Revenue We provide pre-production The following table provides information about contract liabilities from contracts with customers. Deferred Balance at January 1, 2018 $ 2,124 Balance at March 31, 2018 $ 2,204 The timing of revenue recognition, billings and cash collections results in billed accounts receivable and customer advances and deposits (contract liability) on the Condensed Consolidated Balance Sheet. These contract liabilities are reported on the Condensed Consolidated Balance Sheet on a contract-by-contract Transaction Price Allocated to Future Performance Obligations ASC 606 requires that we disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of March 31, 2018. The guidance provides certain practical expedients that limit this requirement. Our contracts meet the following practical expedient provided by ASC 606: • The performance obligation is part of a contract that has an original expected duration of one year or less. Costs to Obtain and Fulfill a Contract Prior to the adoption of ASC 606, we expensed commissions paid to internal sales representatives for obtaining contracts. Under 606 ASC, we adopted the practical expedient to recognize commissions paid to internal sales personnel that are incremental to obtaining customer contracts as an expense when incurred since the amortization period is less than one year. The judgments made in determining the amount of costs incurred include whether the commissions are in fact incremental and would not have occurred absent the customer contract. Costs to obtain a contract are expensed as selling, general and administrative expense. Sales, value add, and other taxes we collect concurrent with revenue-producing activities are excluded from revenue. Incidental items that are immaterial in the context of the contract are recognized as expense. Financial Statement Impact of Adopting ASC 606 The following table presents the impact of adoption of ASC 606 on our condensed consolidated statement of operations and balance sheet. Differences are due to the acceleration in the recognition of revenue to the point of shipment or delivery for contracts where an unconditional obligation to purchase is present for inventory that was considered in consignment under ASC 605. Three Months Ended March 31, 2018 As Reported Balances ASC 606 Effect of Net sales $ 169,148 $ 169,202 $ (54 ) Cost of sales 126,444 126,489 (45 ) Income from operations 3,693 3,702 (9 ) As of March 31, 2018 As Reported Balances Effect of Assets Accounts receivable, net $ 119,615 $ 119,669 $ (54 ) Inventories 91,559 91,514 45 Equity Retained earnings $ 203,159 $ 203,168 $ (9 )

Shared-Based Compensation

Shared-Based Compensation	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Shared-Based Compensation	Note 14. Shared-Based Compensation The following table lists the components of share-based compensation expense by type of award. Three Months Ended March 31, 2018 2017 Stock options $ 205 $ 381 Restricted stock 460 460 Performance share units 591 311 Share-based compensation $ 1,256 $ 1,152 Stock Options During the three months ended March 31, 2018, we granted options to purchase 55,300 shares to certain key employees. The weighted average grant date fair value of the options granted during the three months ended March 31, 2018, was $10.68 per share. The fair value of our options cannot be determined by market value because they are not traded in an open market. Accordingly, we utilized the Black Scholes financial pricing model to estimate the fair value. The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2018. 2018 Expected term 6 years Risk free interest rate 2.65 % Dividend yield 1.14 % Expected volatility 47.78 % Expected forfeiture rate 4.00 % The expected term is derived from using the simplified method of determining stock option terms as described under the Securities and Exchange Commission’s Staff Accounting Bulletin Topic 14, Share-based payment The average risk-free interest rate is derived from United States Department of Treasury published interest rates of daily yield curves for the same time period as the expected term. The expected dividend yield is derived by a mathematical formula which uses the expected annual dividends over the expected term divided by the fair market value of our common stock at the grant date. The expected volatility rate is derived from our actual common stock historical volatility over the same time period as the expected term. The volatility rate is derived by mathematical formula utilizing daily closing price data. The forfeiture rate is determined from examining the historical pre-vesting The following table summarizes option activity for the three months ended March 31, 2018. Options Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2018 746 $ 14.33 Granted 55 24.55 Exercised (23 ) 10.00 $ 238 Outstanding at March 31, 2018 778 $ 15.19 6.4 $ 6,850 (1) Exercisable at March 31, 2018 619 $ 13.44 5.7 $ 6,539 (1) (1) The intrinsic value is the amount by which the market price of our stock was greater than the exercise price of any individual option grant at March 31, 2018. Restricted Stock During the three months ended March 31, 2018, we granted 86,516 restricted stock awards to non-executive pro-rata non-executive The following table summarizes the status of unvested restricted stock awards as of March 31, 2018, and changes during the three months then ended. Nonvested (in thousands) Weighted Grant-Date Nonvested at January 1, 2018 152 $ 19.21 Granted 87 $ 24.55 Vested (80 ) $ 18.88 Nonvested at March 31, 2018 159 $ 22.30 Performance Share Units Performance Share Units (“PSUs”) are a form of long-term incentive compensation awarded to executive officers and certain other key employees designed to directly align the interests of employees to the interests of our stockholders, and to create long-term stockholder value. PSU awards granted in 2018 were made pursuant to the NN, Inc. 2016 Omnibus Incentive Plan and a Performance Share Unit Agreement. Some PSUs are based on total shareholder return (“TSR Awards”), and other PSUs are based on return on invested capital (“ROIC Awards”). The TSR Awards vest, if at all, upon our achieving a specified relative total shareholder return, which will be measured against the total shareholder return of the S&P SmallCap 600 Index during specified performance periods as defined in the award agreements. Each performance period generally begins on January 1 of the year of grant and ends 36 months later on December 31. The ROIC Awards will vest, if at all, upon our achieving a specified average return on invested capital during the performance periods. We recognize compensation expense over the performance period in which the performance and market conditions are measured. If the PSUs do not vest at the end of the performance periods, then the PSUs will expire automatically. Upon vesting, the PSUs will be settled by the issuance of shares of our common stock, subject to the executive officer’s continued employment. The actual number of shares of common stock will be issued to each award recipient at the end of the performance periods will be interpolated between a threshold and maximum payout amount based on actual performance results. No dividends will be paid on outstanding PSUs during the performance period; however, dividend equivalents will be paid based on the number of shares of common stock that are ultimately earned at the end of the Performance Periods. With respect to the TSR Awards, a participant will earn 50% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance.” With respect to the ROIC Awards, a participant will earn 35% of the target number of PSUs for “Threshold Performance,” 100% of the target number of PSUs for “Target Performance,” and 150% of the target number of PSUs for “Maximum Performance. For performance levels falling between the values shown below, the percentages will be determined by interpolation. The following table presents the goals with respect to TSR and ROIC for each award granted in 2018. TSR: Threshold Performance (50% of Shares) Target Performance (100% of Shares) Maximum Performance (150% of Shares) 2018 grants 35th Percentile 50th Percentile 75th Percentile ROIC: Threshold Performance (35% of Shares) Target Performance (100% of Shares) Maximum Performance (150% of Shares) 2018 grants 15.5% 18% 19.5% We estimate the grant date fair value of TSR Awards using the Monte Carlo simulation model, as the total shareholder return metric is considered a market condition under ASC Topic 718, Compensation – stock compensation TSR Awards ROIC Awards Award Year Shares (in thousands) Grant Date Fair Value Shares (in thousands) Grant Date Fair 2018 55 $ 24.65 55 $ 24.55 We generally recognize an expense for ROIC Awards based on the Target Performance threshold of 100% because, at the date of grant, the Target Performance is the probable level of performance achievement. All PSUs that vested on December 31, 2017, were settled in shares in May 2018. The following table summarizes the status of unvested PSU awards as of March 31, 2018, and changes during the period then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares (in thousands) Weighted Grant-Date Shares (in thousands) Weighted Average Fair Value (per share) Nonvested at January 1, 2018 130 $ 16.60 136 $ 16.27 Granted 55 $ 24.65 55 $ 24.55 Forfeited (11 ) $ 15.12 (12 ) $ 15.49 Nonvested at March 31, 2018 174 $ 18.90 179 $ 18.63

Net Income (Loss) Per Share

Net Income (Loss) Per Share	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Net Income (Loss) Per Share	Note 15. Net Income (Loss) Per Share Three Months Ended 2018 2017 Income (loss) from continuing operations $ (5,983 ) $ 1,893 Income from discontinued operations, net of tax — 5,518 Net income (loss) $ (5,983 ) $ 7,411 Weighted average shares outstanding 27,597 27,303 Effect of dilutive stock options — 331 Diluted shares outstanding 27,597 27,634 Basic income (loss) from continuing operations per share $ (0.22 ) $ 0.07 Basic income from discontinued operations per share — 0.20 Basic net income (loss) per share $ (0.22 ) $ 0.27 Diluted income (loss) from continuing operations per share $ (0.22 ) $ 0.07 Diluted income from discontinued operations per share — 0.20 Diluted net income (loss) per share $ (0.22 ) $ 0.27 The calculations of diluted income from continuing operations per share for the three-month periods ended March 31, 2018 and 2017, exclude 0.5 million and 0.6 million potentially dilutive stock options, which had the effect of being anti-dilutive. Given the loss from continuing operations for the three-month period ended March 31, 2018, all options are considered anti-dilutive and were excluded from the calculation of diluted loss from continuing operations per share.

Fair Value Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2018
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 16. Fair Value Measurements Fair value is an exit price representing the expected amount that an entity would receive to sell an asset or pay to transfer a liability in an orderly transaction with market participants at the measurement date. We followed consistent methods and assumptions to estimate fair values as more fully described in the 2017 Annual Report. Our financial instruments that are subject to fair value disclosure consist of cash and cash equivalents, accounts receivable, accounts payable, and long-term debt. As of March 31, 2018, the carrying values of these financial instruments approximated fair value. The fair value of floating-rate debt approximates the carrying amount because the interest rates paid are based on short-term maturities. As of March 31, 2018, we had no fixed-rate debt outstanding. Fair value principles prioritize valuation inputs across three broad levels. Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 inputs are unobservable inputs based on the assumptions used to measure assets and liabilities at fair value. An asset or liability’s classification within the various levels is determined based on the lowest level input that is significant to the fair value measurement. Nonrecurring Fair Value Measurements We completed the Bridgemedica acquisition on February 22, 2018. In connection with our accounting for this acquisition, it was necessary for us to estimate the values of the assets acquired and liabilities assumed, which involved the use of various assumptions discussed in Note 3. We utilized Level 3 inputs to estimate the fair values of these assets and liabilities.

Prior Periods' Financial Statem

Prior Periods' Financial Statement Revision	3 Months Ended
	Mar. 31, 2018
Accounting Changes and Error Corrections [Abstract]
Prior Periods' Financial Statement Revision	Note 17. Prior Periods’ Financial Statement Revision The following tables present the effect of the correction of those misstatements that impacted the three months ended March 31, 2017, as further described in Note 1, and the related adjustments to reflect the revision on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Also, as further described in Note 2, due to the disposition of the PBC Business and the related discontinued operations treatment, the tables below present separately the impact of the correction of the misstatements as well as the effect of recasting the prior periods for discontinued operations. Three Months Ended March 31, 2017 As Originally Adjustment Discontinued As Revised Cost of sales (exclusive of depreciation and amortization) $ 166,954 $ 485 $ (52,959 ) $ 114,480 Selling, general and administrative expense 21,494 (500 ) (4,353 ) 16,641 Depreciation and amortization 15,568 12 (3,009 ) 12,571 Income from operations 22,158 3 (8,309 ) 13,852 Income (loss) from continuing operations before provision (benefit) for income taxes and share of net income from joint venture 8,014 3 (8,194 ) (177 ) Benefit (provision) for income taxes (2,300 ) 1 2,676 377 Income from continuing operations 7,407 4 (5,518 ) 1,893 Income from discontinued operations, net of tax 5,518 5,518 Net income $ 7,407 $ 4 $ 7,411 Other comprehensive income: Foreign currency translation income 4,706 399 5,105 Other comprehensive income (loss): 4,706 399 5,105 Comprehensive income $ 12,113 $ 403 $ 12,516 Basic net income (loss) per share $ 0.27 $ 0.00 $ 0.27 Diluted net income (loss) per share $ 0.27 $ 0.00 $ 0.27 The following table presents the effect of the correction of the misstatements on our Condensed Consolidated Statement of Cash Flows. Three Months Ended March 31, 2017 As Adjustment Reclasses (1) As Net income (loss) $ 7,407 $ 4 $ 7,411 Adjustments to reconcile net income to net cash provided by (used by) operating activities: Depreciation and amortization 15,568 12 15,580 (2) Total derivative mark-to-market (88 ) 88 — Other — (268 ) 61 (207 ) Changes in operating assets and liabilities: Income taxes payable (receivable) — 5,899 5,899 Other 605 (16 ) (6,048 ) (5,459 ) Net cash provided by (used by) operating activities 5,209 (268 ) — 4,941 Cash flows from investing activities Proceeds from disposals of property, plant and equipment 27 — (27 ) — Other — 268 27 295 Net cash provided by (used by) investing activities (8,538 ) 268 — (8,270 ) (1) Includes the reclassification of prior period amounts to reflect current period presentation, including the addition of the income taxes payable (receivable) line as well as condensing immaterial amounts. (2) Depreciation and amortization of $3.0 million is included in income from discontinued operations on the Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2017.

Subsequent Event

Subsequent Event	3 Months Ended
	Mar. 31, 2018
Subsequent Events [Abstract]
Subsequent Event	Note 18. Subsequent Event Paragon Medical Acquisition On May 7, 2018, we acquired 100% of the stock of PMG Intermediate Holding Corporation, the parent company of Paragon Medical, Inc. (“Paragon Medical”) for $375.0 million in cash. Paragon Medical is a medical device manufacturer which focuses on the orthopedic, case and tray, implant and instrument markets. Operating results of Paragon Medical will be reported prospectively in our Life Sciences division. The effects of this acquisition are not reflected in the condensed consolidated financial statements presented in this Quarterly Report on Form 10-Q Second Lien Credit Agreement In connection with the closing, we, certain of our subsidiaries named therein, SunTrust Bank, as Administrative Agent, SunTrust Robinson Humphrey, Inc. as Lead Arranger and Bookrunner, and the lenders named therein entered into a Second Lien Credit Agreement (the “Second Lien Credit Agreement”) pursuant to which SunTrust and the other lenders extended to us a $200.0 million secured second lien term loan facility (the “Second Lien Facility”). We utilized the net proceeds from the Second Lien Facility, together with cash on hand, to pay the Paragon Medical purchase price and fees and expenses related to the acquisition. The Second Lien Facility matures on April 19, 2023, and bears interest at either (i) a base rate, plus an applicable margin, or (ii) the greater of the London Interbank Offered Rate (“LIBOR”) or 1.00%, plus an applicable margin. The initial applicable margin for all borrowings under the Second Lien Facility is 7.00% per annum with respect to base rate borrowings and 8.00% per annum with respect to LIBOR borrowings. We may voluntarily prepay outstanding loans under the Second Lien Facility, in whole or in part without premium or penalty until August 7, 2018, or at any time following May 7, 2020. We may be subject to a prepayment penalty of 2% of the amount of such loans that we prepay between August 7, 2018, and May 7, 2020. If we prepay any outstanding loans after May 7, 2019, but prior to May 7, 2020, we may be subject to a prepayment penalty of 1% of the amount prepaid. The Second Lien Credit Agreement requires us to prepay outstanding loans, subject to certain exceptions, with: (i) a variable percentage of excess cash flow; (ii) 100% of the net cash proceeds of non-ordinary Amendment to Credit Facility On May 7, 2018, we entered into an amendment to our existing credit facility to permit the Paragon Medical acquisition, to permit the Second Lien Credit Agreement, and to amend certain covenants.

Interim Financial Statements (P

Interim Financial Statements (Policies)	3 Months Ended
	Mar. 31, 2018
Quarterly Financial Information Disclosure [Abstract]
Nature of Business	Nature of Business NN, Inc., is a global diversified industrial company that combines advanced engineering and production capabilities with in-depth 10-Q, In January 2018, we implemented a new enterprise and management structure designed to accelerate growth and further balance our portfolio by aligning our strategic assets and businesses. Our businesses were reorganized into the Mobile Solutions, Power Solutions, and Life Sciences divisions and are based principally on the end markets they serve. The Autocam Precision Components Group reported in our historical financial statements was renamed as the Mobile Solutions division. The Mobile Solutions division is focused on growth in the industrial and automotive end markets. The Precision Engineered Products Group reported in our historical financial statements was bifurcated into two new divisions – Power Solutions and Life Sciences. The Power Solutions division is focused on growth in the electrical and aerospace and defense end markets. The Life Sciences division is focused on growth in the medical end market.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements have not been audited, except that the Condensed Consolidated Balance Sheet as of December 31, 2017, was derived from the audited consolidated financial statements included in our Annual Report on Form 10-K Certain information and footnote disclosures normally included in the consolidated financial statements prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) have been condensed or omitted from the interim financial statements presented in this Quarterly Report on Form 10-Q. Except for per share data or as otherwise indicated, all dollar amounts presented in the tables in these Notes to Condensed Consolidated Financial Statements are in thousands.
Prior Periods Financial Statement Revision	Prior Periods’ Financial Statement Revision As disclosed in our 2017 Annual Report on Form10-K, we identified various misstatements in our previously issued 2016 and 2015 annual financial statements and interim periods in 2016 and 2017. These prior period errors related primarily to (i) accounting for income and franchise taxes, (ii) accounting for the gain on the disposition of a business, (iii) accounting for indemnification assets related to a prior acquisition, (iv) accounting for foreign currency transactions, (v) accounting for the translation of foreign subsidiary assets and joint venture, and (vi) other immaterial errors, including errors that had previously been adjusted for as out of period corrections in the periods identified. We assessed the materiality of the misstatements on prior periods’ financial statements in accordance with SEC Staff Accounting Bulletin (“SAB”) Topic 1.M, Materiality, codified in Accounting Standards Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections, (“ASC 250”) and concluded that the misstatements were not material to any prior annual or interim periods. In accordance with ASC 250 (SAB Topic 1.N, Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements
Accounting Standards Recently Adopted	Accounting Standards Recently Adopted Revenue Recognition Revenue from Contracts with Customers Revenue Recognition, Definition of a Business. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business, Statement of Cash Flows. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (a consensus of the Emerging Issues Task Force) The new cash flow guidance requires that cash payments for debt prepayment costs be classified as cash outflows for financing activities. We paid $31.6 million for debt prepayment costs in April 2017. These debt prepayment costs were previously classified as cash outflows from operating activities in 2017. Under the new guidance, these costs will be reclassified to cash outflows from financing activities when these comparable periods are presented in future filings. The new guidance also requires entities to make an accounting policy election regarding classification of distributions received from equity method investees. Existing guidance does not currently address how an entity should determine which distributions represent returns on versus returns of investment. The lack of specific guidance has resulted in diversity in practice. The two allowable approaches are the “cumulative earnings” approach and the “nature of the distribution” approach, as defined by ASU 2016-15. Accounting Standards Not Yet Adopted Leases. 2016-02, Leases 2016-02 Leases, Leases. 2016-02 right-of-use Goodwill. 2017-04, Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment, Effects of Tax Reform in Other Comprehensive Income. 2018-02, Income Statement – Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income, 2018-02

Discontinued Operations (Tables

Discontinued Operations (Tables)	3 Months Ended
	Mar. 31, 2018
Discontinued Operations and Disposal Groups [Abstract]
Summary of Discontinued Operations	The following table summarizes the major line items included in the results of operations of the discontinued operations. Three Months Ended Net sales $ 68,759 Cost of sales (exclusive of depreciation and amortization shown separately below) 52,959 Selling, general and administrative expense 4,353 Depreciation and amortization 3,009 Restructuring and integration expense 129 Income from operations 8,309 Gain on disposal of discontinued operations — Interest income 117 Interest and other income (expense) (2 ) Income from discontinued operations before provision (benefit) for income taxes 8,194 Provision for income taxes 2,676 Income from discontinued operations, net of tax $ 5,518 The following table presents the significant noncash items and cash paid for capital expenditures of discontinued operations. Three Months Ended Depreciation and amortization $ 3,009 Acquisition of property, plant and equipment $ 2,483

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment Information	The following table presents results of continuing operations for each reportable segment. Mobile Power Life Corporate and Total Three Months Ended March 31, 2018 Net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) (a) $ 169,148 Income (loss) from operations $ 9,785 $ 5,233 $ 4,204 $ (15,529 ) $ 3,693 Interest expense (11,996 ) Other income, net 313 Loss from continuing operations before benefit for income taxes and share of net income from joint venture $ (7,990 ) Three Months Ended March 31, 2017 Net sales $ 86,446 $ 48,424 $ 23,129 $ (444 ) $ 157,555 Income (loss) from operations $ 10,601 $ 6,795 $ 3,622 $ (7,166 ) $ 13,852 Interest expense (14,839 ) Other 810 Loss from continuing operations before benefit for income taxes and share of net income from joint venture $ (177 ) (a) Includes eliminations of intersegment transactions occurring during the ordinary course of business. Total Assets as of March 31, December 31, Mobile Solutions $ 453,521 $ 428,321 Power Solutions 393,048 383,063 Life Sciences 362,744 355,703 Corporate and Consolidations 275,769 307,916 Total Continuing Operations $ 1,485,082 $ 1,475,003

Inventories (Tables)

Inventories (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Summary of Inventories	Inventories are comprised of the following amounts: March 31, December 31, Raw materials $ 38,151 $ 37,337 Work in process 32,124 27,669 Finished goods 21,284 17,611 Inventories $ 91,559 $ 82,617

Goodwill (Tables)

Goodwill (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in Carrying Amount of Goodwill	The following table shows changes in the carrying amount of goodwill. Mobile Power Life Total Balance as of December 31, 2017 $ 74,147 $ 201,881 $ 178,584 $ 454,612 Currency impacts 295 719 — 1,014 Goodwill acquired in acquisition — — 7,867 7,867 Adjustments to goodwill — — 201 201 Balance as of March 31, 2018 $ 74,442 $ 202,600 $ 186,652 $ 463,694

Intangible Assets, Net (Tables)

Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Summary of Carrying Amount of Intangible Assets Net	The following table shows changes in the carrying amount of intangible assets, net. Mobile Power Life Total Balance as of December 31, 2017 $ 39,446 $ 105,030 $ 93,226 $ 237,702 Amortization (873 ) (2,725 ) (2,397 ) (5,995 ) Currency impacts (15 ) — — (15 ) Intangible assets acquired in acquisition — — 5,913 5,913 Balance as of March 31, 2018 $ 38,558 $ 102,305 $ 96,742 $ 237,605

Investment in Joint Venture (Ta

Investment in Joint Venture (Tables)	3 Months Ended
	Mar. 31, 2018
Equity Method Investments and Joint Ventures [Abstract]
Summarized Activity Related to Investment in Joint Venture	The following table summarizes activity related to our investment in the JV. Balance as of December 31, 2017 $ 39,822 Our share of cumulative earnings 957 Accretion of basis difference from purchase accounting (126 ) Foreign currency translation gain 1,457 Balance as of March 31, 2018 $ 42,110
Summarized Balance Sheet Information of Unconsolidated Joint Venture	The following tables show selected financial data of the joint venture. March 31, December 31, Current assets $ 58,517 $ 47,600 Non-current 32,844 24,763 Total assets $ 91,361 $ 72,363 Current liabilities $ 41,504 $ 26,165 Total liabilities $ 41,504 $ 26,165
Summarized Income Statement Information of Unconsolidated Joint Venture	Three Months Ended March 31, 2018 2017 Net sales $ 18,003 $ 19,111 Cost of sales $ 15,147 $ 14,436 Income from operations $ 2,508 $ 4,411 Net income $ 1,952 $ 3,689

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Summary of Debt	The following table presents debt balances as of March 31, 2018, and December 31, 2017. March 31, December 31, $545.0 million Senior Secured Term Loan B (“Senior Secured Term Loan”) bearing interest at the greater of 0.75% or one-month $ 534,250 $ 534,250 $300.0 million Incremental Term Loan (“Incremental Term Loan”) bearing interest at one-month LIBOR (1.88% at March 31, 2018), plus an applicable margin of 3.25% at March 31, 2018, expiring April 3, 2021 288,000 291,000 $143.0 million Senior Secured Revolver (“Senior Secured Revolver”) bearing interest at one-month LIBOR (1.88% at March 31, 2018) plus an applicable margin of 3.5% at March 31, 2018, expiring October 19, 2020 — — French Safeguard Obligations 299 290 Brazilian lines of credit and equipment notes 207 257 Chinese line of credit, bearing interest 2,868 2,768 Total 825,624 828,565 Less current maturities of long-term debt 18,796 17,283 Principal, net of current portion 806,828 811,282 Less unamortized debt issuance costs 19,390 20,477 Long-term debt, net of current portion $ 787,438 $ 790,805

Restructuring and Integration (

Restructuring and Integration (Tables)	3 Months Ended
	Mar. 31, 2018
Wheeling Plant [Member]
Summary of Restructuring and Integration Charges and Reserve Activity	The following table summarizes restructuring and integration charges incurred for the three-month periods ended March 31, 2018 and 2017. Three Months Ended March 31, 2018 Mobile Power Life Corporate and Total Severance and other employee costs $ — $ — $ — $ 728 $ 728 Other 27 — — — 27 Total $ 27 $ — $ — $ 728 $ 755 Three Months Ended March 31, 2017 Mobile Power Life Corporate and Total Severance and other employee costs $ 11 $ — $ — $ — $ 11 Total $ 11 $ — $ — $ — $ 11 The following table summarizes restructuring and integration reserve activity for the three months ended March 31, 2018. Reserve Balance as of Charges Non-cash Cash Reserve Balance as of Severance and other employee costs $ — $ 728 $ — $ (95 ) $ 633 Site closure and other associated costs 1,099 27 (31 ) (583 ) 512 Total $ 1,099 $ 755 $ (31 ) $ (678 ) $ 1,145

Revenue from Contracts with C34

Revenue from Contracts with Customers (Tables)	3 Months Ended
	Mar. 31, 2018
Summary of Revenue from Contracts with Customers	The following table summarizes sales to external customers by major source. Three Months Ended March 31, 2018 Mobile Power Life Intersegment Total United States $ 49,655 $ 40,128 $ 30,553 $ (528 ) $ 119,808 China 11,581 1,485 126 — 13,192 Mexico 7,236 3,197 172 — 10,605 Brazil 9,885 50 — — 9,935 Poland 2,052 14 — — 2,066 Czech Republic 1,810 — — — 1,810 Italy 1,577 98 — — 1,675 Germany 1,534 7 1 — 1,542 Switzerland 1,406 — — — 1,406 Netherlands — 974 — — 974 Other 3,058 2,729 348 — 6,135 Total net sales $ 89,794 $ 48,682 $ 31,200 $ (528 ) $ 169,148
Summary of Contract Liabilities from Contracts with Customers	The following table provides information about contract liabilities from contracts with customers. Deferred Balance at January 1, 2018 $ 2,124 Balance at March 31, 2018 $ 2,204
Accounting Standards Update 2014-09 [Member]
Condensed Consolidated Statement of Operations and Balance Sheet	The following table presents the impact of adoption of ASC 606 on our condensed consolidated statement of operations and balance sheet. Differences are due to the acceleration in the recognition of revenue to the point of shipment or delivery for contracts where an unconditional obligation to purchase is present for inventory that was considered in consignment under ASC 605. Three Months Ended March 31, 2018 As Reported Balances ASC 606 Effect of Net sales $ 169,148 $ 169,202 $ (54 ) Cost of sales 126,444 126,489 (45 ) Income from operations 3,693 3,702 (9 ) As of March 31, 2018 As Reported Balances Effect of Assets Accounts receivable, net $ 119,615 $ 119,669 $ (54 ) Inventories 91,559 91,514 45 Equity Retained earnings $ 203,159 $ 203,168 $ (9 )

Shared-Based Compensation (Tabl

Shared-Based Compensation (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components of Share-Based Compensation Expense by Type of Award	The following table lists the components of share-based compensation expense by type of award. Three Months Ended March 31, 2018 2017 Stock options $ 205 $ 381 Restricted stock 460 460 Performance share units 591 311 Share-based compensation $ 1,256 $ 1,152
Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification	The following table shows the weighted average assumptions relevant to determining the fair value of stock options granted in 2018. 2018 Expected term 6 years Risk free interest rate 2.65 % Dividend yield 1.14 % Expected volatility 47.78 % Expected forfeiture rate 4.00 %
Reconciliation of Option Activity	The following table summarizes option activity for the three months ended March 31, 2018. Options Shares Weighted- Weighted- Aggregate Outstanding at January 1, 2018 746 $ 14.33 Granted 55 24.55 Exercised (23 ) 10.00 $ 238 Outstanding at March 31, 2018 778 $ 15.19 6.4 $ 6,850 (1) Exercisable at March 31, 2018 619 $ 13.44 5.7 $ 6,539 (1) (1) The intrinsic value is the amount by which the market price of our stock was greater than the exercise price of any individual option grant at March 31, 2018.
Reconciliation of Restricted Stock Option Activity	The following table summarizes the status of unvested restricted stock awards as of March 31, 2018, and changes during the three months then ended. Nonvested (in thousands) Weighted Grant-Date Nonvested at January 1, 2018 152 $ 19.21 Granted 87 $ 24.55 Vested (80 ) $ 18.88 Nonvested at March 31, 2018 159 $ 22.30
Schedule of Performance Based Awards Goals with Respect to TSR and ROIC	The following table presents the goals with respect to TSR and ROIC for each award granted in 2018. TSR: Threshold Performance (50% of Shares) Target Performance (100% of Shares) Maximum Performance (150% of Shares) 2018 grants 35th Percentile 50th Percentile 75th Percentile ROIC: Threshold Performance (35% of Shares) Target Performance (100% of Shares) Maximum Performance (150% of Shares) 2018 grants 15.5% 18% 19.5%
Schedule of Number of Awards Granted and Grant Date Fair Value of Each Award in Periods	The following table presents the number of awards granted and the grant date fair value of each award in the periods presented. TSR Awards ROIC Awards Award Year Shares (in thousands) Grant Date Fair Value Shares (in thousands) Grant Date Fair 2018 55 $ 24.65 55 $ 24.55
Summary of Status of Unvested PSU Awards	The following table summarizes the status of unvested PSU awards as of March 31, 2018, and changes during the period then ended. Nonvested TSR Awards Nonvested ROIC Awards Shares (in thousands) Weighted Grant-Date Shares (in thousands) Weighted Average Fair Value (per share) Nonvested at January 1, 2018 130 $ 16.60 136 $ 16.27 Granted 55 $ 24.65 55 $ 24.55 Forfeited (11 ) $ 15.12 (12 ) $ 15.49 Nonvested at March 31, 2018 174 $ 18.90 179 $ 18.63

Net Income (Loss) Per Share (Ta

Net Income (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Summary of Net Income (Loss) Per Share	Three Months Ended 2018 2017 Income (loss) from continuing operations $ (5,983 ) $ 1,893 Income from discontinued operations, net of tax — 5,518 Net income (loss) $ (5,983 ) $ 7,411 Weighted average shares outstanding 27,597 27,303 Effect of dilutive stock options — 331 Diluted shares outstanding 27,597 27,634 Basic income (loss) from continuing operations per share $ (0.22 ) $ 0.07 Basic income from discontinued operations per share — 0.20 Basic net income (loss) per share $ (0.22 ) $ 0.27 Diluted income (loss) from continuing operations per share $ (0.22 ) $ 0.07 Diluted income from discontinued operations per share — 0.20 Diluted net income (loss) per share $ (0.22 ) $ 0.27

Prior Periods' Financial Stat37

Prior Periods' Financial Statement Revision (Tables)	3 Months Ended
	Mar. 31, 2018
Accounting Changes and Error Corrections [Abstract]
Schedule of Correction of Misstatements and Revision on Consolidated Statements	The following tables present the effect of the correction of those misstatements that impacted the three months ended March 31, 2017, as further described in Note 1, and the related adjustments to reflect the revision on the Condensed Consolidated Statements of Operations and Comprehensive Income (Loss). Also, as further described in Note 2, due to the disposition of the PBC Business and the related discontinued operations treatment, the tables below present separately the impact of the correction of the misstatements as well as the effect of recasting the prior periods for discontinued operations. Three Months Ended March 31, 2017 As Originally Adjustment Discontinued As Revised Cost of sales (exclusive of depreciation and amortization) $ 166,954 $ 485 $ (52,959 ) $ 114,480 Selling, general and administrative expense 21,494 (500 ) (4,353 ) 16,641 Depreciation and amortization 15,568 12 (3,009 ) 12,571 Income from operations 22,158 3 (8,309 ) 13,852 Income (loss) from continuing operations before provision (benefit) for income taxes and share of net income from joint venture 8,014 3 (8,194 ) (177 ) Benefit (provision) for income taxes (2,300 ) 1 2,676 377 Income from continuing operations 7,407 4 (5,518 ) 1,893 Income from discontinued operations, net of tax 5,518 5,518 Net income $ 7,407 $ 4 $ 7,411 Other comprehensive income: Foreign currency translation income 4,706 399 5,105 Other comprehensive income (loss): 4,706 399 5,105 Comprehensive income $ 12,113 $ 403 $ 12,516 Basic net income (loss) per share $ 0.27 $ 0.00 $ 0.27 Diluted net income (loss) per share $ 0.27 $ 0.00 $ 0.27 The following table presents the effect of the correction of the misstatements on our Condensed Consolidated Statement of Cash Flows. Three Months Ended March 31, 2017 As Adjustment Reclasses (1) As Net income (loss) $ 7,407 $ 4 $ 7,411 Adjustments to reconcile net income to net cash provided by (used by) operating activities: Depreciation and amortization 15,568 12 15,580 (2) Total derivative mark-to-market (88 ) 88 — Other — (268 ) 61 (207 ) Changes in operating assets and liabilities: Income taxes payable (receivable) — 5,899 5,899 Other 605 (16 ) (6,048 ) (5,459 ) Net cash provided by (used by) operating activities 5,209 (268 ) — 4,941 Cash flows from investing activities Proceeds from disposals of property, plant and equipment 27 — (27 ) — Other — 268 27 295 Net cash provided by (used by) investing activities (8,538 ) 268 — (8,270 ) (1) Includes the reclassification of prior period amounts to reflect current period presentation, including the addition of the income taxes payable (receivable) line as well as condensing immaterial amounts. (2) Depreciation and amortization of $3.0 million is included in income from discontinued operations on the Condensed Consolidated Statements of Operations and Comprehensive Income for the three months ended March 31, 2017.

Interim Financial Statements -

Interim Financial Statements - Additional Information (Detail) $ in Thousands	Apr. 30, 2017USD ($)	Mar. 31, 2018USD ($)Facility	Mar. 31, 2017USD ($)
Interim Reporting [Line Items]
Number of manufacturing facilities | Facility		44
Net profit change on contracts		$ (5,983)	$ 7,411
Cash paid for debt prepayment	$ 31,600
Maximum [Member] | Accounting Standards Update 2014-09 [Member]
Interim Reporting [Line Items]
Net profit change on contracts		$ 100

Discontinued Operations - Summa

Discontinued Operations - Summary of Major Line Items Included in Results of Operations of Discontinued Operations (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]
Net sales	$ 68,759
Cost of sales (exclusive of depreciation and amortization shown separately below)	52,959
Selling, general and administrative expense	4,353
Depreciation and amortization	3,009
Restructuring and integration expense	129
Income from operations	8,309
Gain on disposal of discontinued operations	0
Interest income	117
Interest and other income (expense)	(2)
Income from discontinued operations before provision (benefit) for income taxes	8,194
Provision for income taxes	2,676
Income from discontinued operations, net of tax	$ 5,518

Discontinued Operations - Sum40

Discontinued Operations - Summary of Significant Noncash Items and Cash Paid for Capital Expenditures of Discontinued Operations (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Discontinued Operation, Alternative Cash Flow Information [Abstract]
Depreciation and amortization	$ 3,009
Acquisition of property, plant and equipment	$ 2,483

Acquisitions - Additional Infor

Acquisitions - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2018	Feb. 22, 2018
Business Acquisition [Line Items]
Cash paid for earnest money		$ 6,000
Bridgemedica, LLC [Member]
Business Acquisition [Line Items]
Date of acquisition		Feb. 22, 2018
Acquisition percentage			100.00%
Paragon Medical Inc [Member]
Business Acquisition [Line Items]
Date of acquisition		May 7, 2018
Cash paid for earnest money	$ 6,000

Segment Information - Segment I

Segment Information - Segment Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Segment Reporting Information [Line Items]
Net sales	$ 169,148	$ 157,555
Income (loss) from operations	3,693	13,852
Interest expense	(11,996)	(14,839)
Other income, net	313	722
Other		810
Loss from continuing operations before benefit for income taxes and share of net income from joint venture	(7,990)	(177)
Total assets	1,485,082		$ 1,475,003
Mobile Solutions [Member]
Segment Reporting Information [Line Items]
Net sales	89,794	86,446
Income (loss) from operations	9,785	10,601
Total assets	453,521		428,321
Power Solutions [Member]
Segment Reporting Information [Line Items]
Net sales	48,682	48,424
Income (loss) from operations	5,233	6,795
Total assets	393,048		383,063
Life Sciences [Member]
Segment Reporting Information [Line Items]
Net sales	31,200	23,129
Income (loss) from operations	4,204	3,622
Total assets	362,744		355,703
Corporate and Consolidations [Member]
Segment Reporting Information [Line Items]
Net sales	(528)	(444)
Income (loss) from operations	(15,529)	$ (7,166)
Total assets	$ 275,769		$ 307,916

Segment Information - Additiona

Segment Information - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2018	Mar. 31, 2017
Segment Reporting Information [Line Items]
Sales revenue		$ 169,148	$ 157,555
Net income		$ (5,983)	$ 7,411
Bridgemedica, LLC [Member]
Segment Reporting Information [Line Items]
Sales revenue	$ 1,300
Net income	$ 100

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory Disclosure [Abstract]
Raw materials	$ 38,151	$ 37,337
Work in process	32,124	27,669
Finished goods	21,284	17,611
Inventories	$ 91,559	$ 82,617

Goodwill - Changes in Carrying

Goodwill - Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Goodwill [Line Items]
Beginning Balance	$ 454,612
Currency impacts	1,014
Goodwill acquired in acquisition	7,867
Adjustments to goodwill	201
Ending Balance	463,694
Mobile Solutions [Member]
Goodwill [Line Items]
Beginning Balance	74,147
Currency impacts	295
Ending Balance	74,442
Power Solutions [Member]
Goodwill [Line Items]
Beginning Balance	201,881
Currency impacts	719
Ending Balance	202,600
Life Sciences [Member]
Goodwill [Line Items]
Beginning Balance	178,584
Goodwill acquired in acquisition	7,867
Adjustments to goodwill	201
Ending Balance	$ 186,652

Intangible Assets, Net - Summar

Intangible Assets, Net - Summary of Carrying Amount of Intangible Assets by Segment (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	$ 237,702
Amortization	(5,995)
Currency impacts	(15)
Intangible assets acquired in acquisition	5,913
Ending balance	237,605
Mobile Solutions [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	39,446
Amortization	(873)
Currency impacts	(15)
Ending balance	38,558
Power Solutions [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	105,030
Amortization	(2,725)
Ending balance	102,305
Life Sciences [Member]
Finite-Lived Intangible Assets [Line Items]
Beginning Balance	93,226
Amortization	(2,397)
Intangible assets acquired in acquisition	5,913
Ending balance	$ 96,742

Intangible Assets, Net - Additi

Intangible Assets, Net - Additional Information (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 5,913
Bridgemedica, LLC [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets	$ 5,900
Estimated intangible assets useful life	13 years

Investment in Joint Venture - A

Investment in Joint Venture - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Schedule of Equity Method Investments [Line Items]
Net sales	$ 169,148,000	$ 157,555,000
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Net sales		$ 100,000
Joint Venture [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Net sales	$ 200,000
Wuxi Weifu Autocam Precision Machinery Company, Ltd. [Member]
Schedule of Equity Method Investments [Line Items]
Investment in joint venture	49.00%

Investment in Joint Venture - S

Investment in Joint Venture - Summarized Activity Related to Investment in Joint Venture (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Schedule of Equity Method Investments [Line Items]
Beginning Balance	$ 39,822
Our share of cumulative earnings	831	$ 1,693
Ending Balance	42,110
Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Beginning Balance	39,822
Our share of cumulative earnings	957
Accretion of basis difference from purchase accounting	(126)
Foreign currency translation gain	1,457
Ending Balance	$ 42,110

Investment in Joint Venture -50

Investment in Joint Venture - Summarized Balance Sheet Information of Unconsolidated Joint Venture (Detail) - Joint Venture [Member] - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Schedule of Equity Method Investments [Line Items]
Current assets	$ 58,517	$ 47,600
Non-current assets	32,844	24,763
Total assets	91,361	72,363
Current liabilities	41,504	26,165
Total liabilities	$ 41,504	$ 26,165

Investment in Joint Venture -51

Investment in Joint Venture - Summarized Income Statement Information of Unconsolidated Joint Venture (Detail) - Joint Venture [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Schedule of Equity Method Investments [Line Items]
Net sales	$ 18,003	$ 19,111
Cost of sales	15,147	14,436
Income from operations	2,508	4,411
Net income	$ 1,952	$ 3,689

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Income Tax Disclosure [Abstract]
U.S. federal statutory rate	21.00%		35.00%
Effective tax rate from continuing operations	14.70%	213.00%

Debt - Summary of Debt (Detail)

Debt - Summary of Debt (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Total	$ 825,624	$ 828,565
Less current maturities of long-term debt	18,796	17,283
Principal, net of current portion	806,828	811,282
Less unamortized debt issuance costs	19,390	20,477
Long-term debt, net of current portion	787,438	790,805
French Safeguard [Member]
Debt Instrument [Line Items]
French Safeguard Obligations	299	290
Brazilian [Member]
Debt Instrument [Line Items]
Line of credit	207	257
Chinese [Member]
Debt Instrument [Line Items]
Line of credit	2,868	2,768
Senior Secured Term Loan B [Member]
Debt Instrument [Line Items]
Senior debt	534,250	534,250
Incremental Term Loan [Member]
Debt Instrument [Line Items]
Senior debt	$ 288,000	$ 291,000

Debt - Summary of Debt (Parenth

Debt - Summary of Debt (Parenthetical) (Detail) - London Interbank Offered Rate (LIBOR) [Member]	3 Months Ended
	Mar. 31, 2018USD ($)
Senior Secured Term Loan B [Member]
Debt Instrument [Line Items]
Borrowings	$ 545,000,000
Interest rate	1.88%
Applicable margin	3.75%
LIBOR Period	1 month
Debt maturity date	Oct. 19, 2022
Senior Secured Term Loan B [Member] | Minimum [Member]
Debt Instrument [Line Items]
Interest rate	0.75%
Incremental Term Loan [Member]
Debt Instrument [Line Items]
Borrowings	$ 300,000,000
Interest rate	1.88%
Applicable margin	3.25%
LIBOR Period	1 month
Debt maturity date	Apr. 3, 2021
Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Borrowings	$ 143,000,000
Interest rate	1.88%
Applicable margin	3.50%
Debt maturity date	Oct. 19, 2020

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Debt Disclosure [Abstract]
Capitalized interest costs	$ 0.2	$ 0.4

Restructuring and Integration -

Restructuring and Integration - Summary of Restructuring and Integration Charges and Reserve Activity (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	$ 728	$ 11
Other	27
Total	755	11
Reserve beginning balance	1,099
Charges	755
Non-cash Adjustments	(31)
Cash Reductions	(678)
Reserve ending balance	1,145
Severance and Other Employee Costs [Member]
Restructuring Cost and Reserve [Line Items]
Charges	728
Cash Reductions	(95)
Reserve ending balance	633
Site Closure and Other Associated Costs [Member]
Restructuring Cost and Reserve [Line Items]
Reserve beginning balance	1,099
Charges	27
Non-cash Adjustments	(31)
Cash Reductions	(583)
Reserve ending balance	512
Mobile Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs		11
Other	27
Total	27	$ 11
Corporate and Consolidations [Member]
Restructuring Cost and Reserve [Line Items]
Severance and other employee costs	728
Total	$ 728

Restructuring and Integration57

Restructuring and Integration - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Restructuring Cost and Reserve [Line Items]
Severance costs	$ 728	$ 11
Precision Engineered Products Group [Member]
Restructuring Cost and Reserve [Line Items]
Severance costs	$ 700

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Contingencies And Commitments [Line Items]
Amount accrued for estimation of loss	$ 0	$ 0
Minimum [Member]
Contingencies And Commitments [Line Items]
Possible loss estimated	0
Maximum [Member]
Contingencies And Commitments [Line Items]
Possible loss estimated	$ 6,000,000

Revenue from Contracts with C59

Revenue from Contracts with Customers - Summary of Revenue from Contracts with Customers (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue, Major Customer [Line Items]
Net sales	$ 169,148	$ 157,555
Intersegment Sales Eliminations [Member]
Revenue, Major Customer [Line Items]
Net sales	(528)
United States [Member]
Revenue, Major Customer [Line Items]
Net sales	119,808
United States [Member] | Intersegment Sales Eliminations [Member]
Revenue, Major Customer [Line Items]
Net sales	(528)
Chinese [Member]
Revenue, Major Customer [Line Items]
Net sales	13,192
Mexico [Member]
Revenue, Major Customer [Line Items]
Net sales	10,605
Brazilian [Member]
Revenue, Major Customer [Line Items]
Net sales	9,935
Poland [Member]
Revenue, Major Customer [Line Items]
Net sales	2,066
Czech Republic [Member]
Revenue, Major Customer [Line Items]
Net sales	1,810
Germany [Member]
Revenue, Major Customer [Line Items]
Net sales	1,542
Italy [Member]
Revenue, Major Customer [Line Items]
Net sales	1,675
Switzerland [Member]
Revenue, Major Customer [Line Items]
Net sales	1,406
Netherlands [Member]
Revenue, Major Customer [Line Items]
Net sales	974
Other Country [Member]
Revenue, Major Customer [Line Items]
Net sales	6,135
Mobile Solutions [Member]
Revenue, Major Customer [Line Items]
Net sales	89,794	86,446
Mobile Solutions [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	89,794
Mobile Solutions [Member] | United States [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	49,655
Mobile Solutions [Member] | Chinese [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	11,581
Mobile Solutions [Member] | Mexico [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	7,236
Mobile Solutions [Member] | Brazilian [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	9,885
Mobile Solutions [Member] | Poland [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	2,052
Mobile Solutions [Member] | Czech Republic [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	1,810
Mobile Solutions [Member] | Germany [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	1,534
Mobile Solutions [Member] | Italy [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	1,577
Mobile Solutions [Member] | Switzerland [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	1,406
Mobile Solutions [Member] | Other Country [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	3,058
Power Solutions [Member]
Revenue, Major Customer [Line Items]
Net sales	48,682	48,424
Power Solutions [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	48,682
Power Solutions [Member] | United States [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	40,128
Power Solutions [Member] | Chinese [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	1,485
Power Solutions [Member] | Mexico [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	3,197
Power Solutions [Member] | Brazilian [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	50
Power Solutions [Member] | Poland [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	14
Power Solutions [Member] | Germany [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	7
Power Solutions [Member] | Italy [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	98
Power Solutions [Member] | Netherlands [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	974
Power Solutions [Member] | Other Country [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	2,729
Life Sciences [Member]
Revenue, Major Customer [Line Items]
Net sales	31,200	$ 23,129
Life Sciences [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	31,200
Life Sciences [Member] | United States [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	30,553
Life Sciences [Member] | Chinese [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	126
Life Sciences [Member] | Mexico [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	172
Life Sciences [Member] | Germany [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	1
Life Sciences [Member] | Other Country [Member] | Operating Segments [Member]
Revenue, Major Customer [Line Items]
Net sales	$ 348

Revenue from Contracts with C60

Revenue from Contracts with Customers - Summary of Contract Liabilities from Contracts with Customers (Detail) $ in Thousands	Mar. 31, 2018USD ($)
Contract with Customer, Liability [Abstract]
Deferred Revenue, Beginning Balance	$ 2,124
Deferred Revenue, Ending Balance	$ 2,204

Revenue from Contract with Cust

Revenue from Contract with Customers - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2018USD ($)
Contract with Customer, Liability [Abstract]
Amounts included in deferred revenue for performance obligations satisfied or partially satisfied	$ 0.3

Revenue from Contracts with C62

Revenue from Contracts with Customers - Condensed Consolidated Statement of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales	$ 169,148	$ 157,555
Cost of sales	126,444	114,480
Income from operations	3,693	$ 13,852
Balances Without Adoption of ASC 606 [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales	169,202
Cost of sales	126,489
Income from operations	3,702
Effect of Change [Member] | Accounting Standards Update 2014-09 [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Net sales	(54)
Cost of sales	(45)
Income from operations	$ (9)

Revenue from Contracts with C63

Revenue from Contracts with Customers - Condensed Consolidated Statement of Balance Sheet (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Assets
Accounts receivable, net	$ 119,615	$ 108,446
Inventories	91,559	$ 82,617
Equity
Retained earnings	203,159
Balances Without Adoption of ASC 606 [Member] | Accounting Standards Update 2014-09 [Member]
Assets
Accounts receivable, net	119,669
Inventories	91,514
Equity
Retained earnings	203,168
Effect of Change [Member] | Accounting Standards Update 2014-09 [Member]
Assets
Accounts receivable, net	(54)
Inventories	45
Equity
Retained earnings	$ (9)

Shared-Based Compensation - Com

Shared-Based Compensation - Components of Share-Based Compensation Expense by Type of Award (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 1,256	$ 1,152
Stock Option Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	205	381
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock	460	460
Performance Based Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation	$ 591	$ 311

Shared-Based Compensation - Add

Shared-Based Compensation - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of options granted	55,300
Weighted average grant date fair value of the options granted | $ / shares	$ 10.68
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued	86,516
Stock awards granted vesting period	3 years
Fair value assumptions, exercise price | $ / shares	$ 24.55
TSR Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued	55,000
Percentage of shares issuable based on threshold performance	50.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
ROIC Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock units issued	55,000
Percentage of shares issuable based on threshold performance	35.00%
Percentage of shares issuable based on target performance	100.00%
Percentage of shares issuable based on maximum performance	150.00%
Officers and Key Employees [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	3 years
Non-executive Directors [Member] | Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock awards granted vesting period	1 year

Shared-Based Compensation - Wei

Shared-Based Compensation - Weighted Average Assumptions Relevant to Determining the Fair Value at the Dates of Grant and Stock Option Modification (Detail) - Stock Option Awards [Member]	3 Months Ended
	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	6 years
Risk free interest rate	2.65%
Dividend yield	1.14%
Expected volatility	47.78%
Expected forfeiture rate	4.00%

Shared-Based Compensation - Rec

Shared-Based Compensation - Reconciliation of Option Activity (Detail) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018USD ($)$ / sharesshares
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of options, Outstanding, Beginning Balance | shares	746,000
Number of Options, Granted | shares	55,300
Number of Options, Exercised | shares	(23,000)
Number of Options, Outstanding, Ending Balance | shares	778,000
Number of Options, Options Exercisable | shares	619,000
Weighted-Average Exercise Price, Outstanding, Beginning Balance | $ / shares	$ 14.33
Weighted-Average Exercise Price, Granted | $ / shares	24.55
Weighted-Average Exercise Price, Exercised | $ / shares	10
Weighted-Average Exercise Price, Outstanding, Ending Balance | $ / shares	15.19
Weighted-Average Exercise Price, Options exercisable | $ / shares	$ 13.44
Weighted-Average Remaining Contractual Term, Outstanding	6 years 4 months 24 days
Weighted- Average Remaining Contractual Term, Options exercisable	5 years 8 months 12 days
Aggregate Intrinsic Value, Exercised | $	$ 238
Aggregate Intrinsic Value, Outstanding | $	6,850
Aggregate Intrinsic Value, Options exercisable | $	$ 6,539

Shared-Based Compensation - R68

Shared-Based Compensation - Reconciliation of Restricted Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested Restricted Shares, Beginning Balance | shares	152,000
Nonvested Restricted Shares, Granted | shares	86,516
Nonvested Restricted Shares, Vested | shares	(80,000)
Nonvested Restricted Shares, Ending balance | shares	159,000
Weighted Average Grant-Date Fair Value, Beginning Balance | $ / shares	$ 19.21
Weighted Average Grant-Date Fair Value, Granted | $ / shares	24.55
Weighted Average Grant-Date Fair Value, Vested | $ / shares	18.88
Weighted Average Grant-Date Fair Value, Ending balance | $ / shares	$ 22.30
TSR Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested Restricted Shares, Beginning Balance | shares	130,000
Nonvested Restricted Shares, Granted | shares	55,000
Nonvested Restricted Shares, Forfeited | shares	(11,000)
Nonvested Restricted Shares, Ending balance | shares	174,000
Weighted Average Grant-Date Fair Value, Beginning Balance | $ / shares	$ 16.60
Weighted Average Grant-Date Fair Value, Granted | $ / shares	24.65
Weighted Average Grant-Date Fair Value, Forfeited | $ / shares	15.12
Weighted Average Grant-Date Fair Value, Ending balance | $ / shares	$ 18.90
ROIC Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Nonvested Restricted Shares, Beginning Balance | shares	136,000
Nonvested Restricted Shares, Granted | shares	55,000
Nonvested Restricted Shares, Forfeited | shares	(12,000)
Nonvested Restricted Shares, Ending balance | shares	179,000
Weighted Average Grant-Date Fair Value, Beginning Balance | $ / shares	$ 16.27
Weighted Average Grant-Date Fair Value, Granted | $ / shares	24.55
Weighted Average Grant-Date Fair Value, Forfeited | $ / shares	15.49
Weighted Average Grant-Date Fair Value, Ending balance | $ / shares	$ 18.63

Shared-Based Compensation - Sch

Shared-Based Compensation - Schedule of Performance Based Awards Goals with Respect to TSR and ROIC (Detail)	3 Months Ended
	Mar. 31, 2018
TSR Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold Performance of Shares, percentage	50.00%
Target Performance of Shares, percentage	100.00%
Maximum Performance of Shares, percentage	150.00%
Threshold Performance, percentage	35.00%
Target Performance, percentage	50.00%
Maximum Performance, percentage	75.00%
ROIC Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Threshold Performance of Shares, percentage	35.00%
Target Performance of Shares, percentage	100.00%
Maximum Performance of Shares, percentage	150.00%
Threshold Performance, percentage	15.50%
Target Performance, percentage	18.00%
Maximum Performance, percentage	19.50%

Shared-Based Compensation - Sum

Shared-Based Compensation - Summary of Number of Awards Granted and Grand Date Fair Value (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2018$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant Date Fair Value	$ 24.55
TSR Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted in fair values, Shares | shares	55
Grant Date Fair Value	$ 24.65
ROIC Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of awards granted in fair values, Shares | shares	55
Grant Date Fair Value	$ 24.55

Net Income (Loss) Per Share - S

Net Income (Loss) Per Share - Summary of Net Income (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Earnings Per Share [Abstract]
Income (loss) from continuing operations	$ (5,983)	$ 1,893
Income from discontinued operations, net of tax		5,518
Net income (loss)	$ (5,983)	$ 7,411
Weighted average shares outstanding	27,597	27,303
Effect of dilutive stock options		331
Diluted shares outstanding	27,597	27,634
Basic income (loss) from continuing operations per share	$ (0.22)	$ 0.07
Basic income from discontinued operations per share		0.20
Basic net income (loss) per share	(0.22)	0.27
Diluted income (loss) from continuing operations per share	(0.22)	0.07
Diluted income from discontinued operations per share		0.20
Diluted net income (loss) per share	$ (0.22)	$ 0.27

Net Income (Loss) Per Share - A

Net Income (Loss) Per Share - Additional Information (Detail) - shares shares in Millions	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Stock Option Awards [Member]
Net Income Per Share [Line Items]
Anti-dilutive securities excluded from the calculation of diluted earnings per share from continuing operation	0.5	0.6

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	Mar. 31, 2018USD ($)
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Fair value of fixed-rate debt	$ 0

Prior Periods Financial Stateme

Prior Periods Financial Statement Revision - Schedule of Correction of Misstatements and Revision on Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Changes And Error Corrections [Line Items]
Cost of sales (exclusive of depreciation and amortization)	$ 126,444	$ 114,480
Selling, general and administrative expense	22,177	16,641
Depreciation and amortization	14,281	12,571
Income from operations	3,693	13,852
Income (loss) from continuing operations before provision (benefit) for income taxes and share of net income from joint venture	(7,990)	(177)
Benefit (provision) for income taxes	1,176	377
Income from continuing operations	(5,983)	1,893
Income from discontinued operations, net of tax		5,518
Net income	(5,983)	7,411
Other comprehensive income:
Foreign currency translation income	5,465	5,105
Other comprehensive income (loss):	5,465	5,105
Comprehensive income (loss)	$ (518)	$ 12,516
Basic net income (loss) per share	$ (0.22)	$ 0.27
Diluted net income (loss) per share	$ (0.22)	$ 0.27
As Previously Reported [Member]
Accounting Changes And Error Corrections [Line Items]
Cost of sales (exclusive of depreciation and amortization)		$ 166,954
Selling, general and administrative expense		21,494
Depreciation and amortization		15,568
Income from operations		22,158
Income (loss) from continuing operations before provision (benefit) for income taxes and share of net income from joint venture		8,014
Benefit (provision) for income taxes		(2,300)
Income from continuing operations		7,407
Net income		7,407
Other comprehensive income:
Foreign currency translation income		4,706
Other comprehensive income (loss):		4,706
Comprehensive income (loss)		$ 12,113
Basic net income (loss) per share		$ 0.27
Diluted net income (loss) per share		$ 0.27
Adjustment [Member]
Accounting Changes And Error Corrections [Line Items]
Cost of sales (exclusive of depreciation and amortization)		$ 485
Selling, general and administrative expense		(500)
Depreciation and amortization		12
Income from operations		3
Income (loss) from continuing operations before provision (benefit) for income taxes and share of net income from joint venture		3
Benefit (provision) for income taxes		1
Income from continuing operations		4
Net income		4
Other comprehensive income:
Foreign currency translation income		399
Other comprehensive income (loss):		399
Comprehensive income (loss)		$ 403
Basic net income (loss) per share		$ 0
Diluted net income (loss) per share		$ 0
Discontinued Operations [Member]
Accounting Changes And Error Corrections [Line Items]
Cost of sales (exclusive of depreciation and amortization)		$ (52,959)
Selling, general and administrative expense		(4,353)
Depreciation and amortization		(3,009)
Income from operations		(8,309)
Income (loss) from continuing operations before provision (benefit) for income taxes and share of net income from joint venture		(8,194)
Benefit (provision) for income taxes		2,676
Income from continuing operations		(5,518)
Income from discontinued operations, net of tax		5,518
Continuing Operations As Revised [Member]
Accounting Changes And Error Corrections [Line Items]
Cost of sales (exclusive of depreciation and amortization)		114,480
Selling, general and administrative expense		16,641
Depreciation and amortization		12,571
Income from operations		13,852
Income (loss) from continuing operations before provision (benefit) for income taxes and share of net income from joint venture		(177)
Benefit (provision) for income taxes		377
Income from continuing operations		1,893
Income from discontinued operations, net of tax		5,518
Net income		7,411
Other comprehensive income:
Foreign currency translation income		5,105
Other comprehensive income (loss):		5,105
Comprehensive income (loss)		$ 12,516
Basic net income (loss) per share		$ 0.27
Diluted net income (loss) per share		$ 0.27

Prior Periods Financial State75

Prior Periods Financial Statement Revision - Schedule of Correction of Misstatements and Revision on Condensed Consolidated Statements of Cash Flow (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Changes And Error Corrections [Line Items]
Net income (loss)	$ (5,983)	$ 7,411
Adjustments to reconcile net income to net cash provided by (used by) operating activities:
Other	347	(207)
Changes in operating assets and liabilities:
Income taxes payable (receivable)	(613)	5,899
Other	7,001	(5,459)
Net cash provided by (used by) operating activities	(974)	4,941
Other	(282)	295
Net cash provided by (used by) investing activities	$ (32,818)	(8,270)
As Previously Reported [Member]
Accounting Changes And Error Corrections [Line Items]
Net income (loss)		7,407
Adjustments to reconcile net income to net cash provided by (used by) operating activities:
Depreciation and amortization		15,568
Total derivative mark-to-market gains, net of cash settlements		(88)
Changes in operating assets and liabilities:
Other		605
Net cash provided by (used by) operating activities		5,209
Proceeds from disposals of property, plant and equipment		27
Net cash provided by (used by) investing activities		(8,538)
Adjustment [Member]
Accounting Changes And Error Corrections [Line Items]
Net income (loss)		4
Adjustments to reconcile net income to net cash provided by (used by) operating activities:
Depreciation and amortization		12
Other		(268)
Changes in operating assets and liabilities:
Other		(16)
Net cash provided by (used by) operating activities		(268)
Other		268
Net cash provided by (used by) investing activities		268
Reclasses [Member]
Adjustments to reconcile net income to net cash provided by (used by) operating activities:
Total derivative mark-to-market gains, net of cash settlements		88
Other		61
Changes in operating assets and liabilities:
Income taxes payable (receivable)		5,899
Other		(6,048)
Proceeds from disposals of property, plant and equipment		(27)
Other		27
Continuing Operations As Revised [Member]
Accounting Changes And Error Corrections [Line Items]
Net income (loss)		7,411
Adjustments to reconcile net income to net cash provided by (used by) operating activities:
Depreciation and amortization		15,580
Other		(207)
Changes in operating assets and liabilities:
Income taxes payable (receivable)		5,899
Other		(5,459)
Net cash provided by (used by) operating activities		4,941
Other		295
Net cash provided by (used by) investing activities		$ (8,270)

Prior Periods Financial State76

Prior Periods Financial Statement Revision - Schedule of Correction of Misstatements and Revision on Condensed Consolidated Statements of Cash Flow (Parenthetical) (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Accounting Changes and Error Corrections [Abstract]
Depreciation and amortization	$ 3,009

Subsequent Event - Additional I

Subsequent Event - Additional Information (Detail) - USD ($) $ in Millions	May 07, 2018	Mar. 31, 2018	May 07, 2020	May 07, 2020
Paragon Medical Inc [Member]
Subsequent Event [Line Items]
Date of acquisition		May 7, 2018
Paragon Medical Inc [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Acquisition percentage	100.00%
Cash payment to acquire business	$ 375
Second Lien Credit Agreement [Member] | Sun Trust Bank [Member]
Subsequent Event [Line Items]
Second lien facility maturity date		Apr. 19, 2023
Cash proceeds of non-ordinary course asset sales or other dispositions of property required to prepay outstanding loans		100.00%
Cash proceeds from insurance and condemnation events with respect to assets required to prepay outstanding loans		100.00%
Cash proceeds from the issuance of debt obligations not permitted by credit agreement required to prepay outstanding loans		100.00%
Cash proceeds from the issuance of equity required to prepay outstanding loans		100.00%
Second Lien Credit Agreement [Member] | Sun Trust Bank [Member] | Subsequent Event [Member]
Subsequent Event [Line Items]
Borrowings	$ 200
London Interbank Offered Rate (LIBOR) [Member] | Second Lien Credit Agreement [Member] | Sun Trust Bank [Member]
Subsequent Event [Line Items]
Applicable margin		8.00%
London Interbank Offered Rate (LIBOR) [Member] | Minimum [Member] | Second Lien Credit Agreement [Member] | Sun Trust Bank [Member]
Subsequent Event [Line Items]
Base rate		1.00%
Base Rate [Member] | Second Lien Credit Agreement [Member] | Sun Trust Bank [Member]
Subsequent Event [Line Items]
Applicable margin		7.00%
Scenario, Forecast [Member] | Second Lien Credit Agreement [Member] | Sun Trust Bank [Member]
Subsequent Event [Line Items]
Prepayment penalty percentage			1.00%	2.00%